A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30actual
Sites
1
Country
Austria
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-26 | actual | When the study began enrolling |
| Primary completion | 2025-03-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-14 | actual | The whole study's end, after follow-up |
| First posted | 2024-03-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus, Type 2
Interventions
- Drug: Insulin icodec
- Drug: Insulin degludec
Primary outcome
what the primary-completion date above is the date OFTime below range, glucose less than (<) 3.0 millimoles per liter (mmol/L) (54 milligrams per deciliter [mg/dL]) within 24 hours after start of exercise (TBR3.0mmol/L,exe)
measured 0-24 hours after start of exercise at Day 38
Publications
- PMID 42387301 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed